Welch & Forbes LLC Acquires Shares of 19,535 Ralliant Corporation $RAL

Welch & Forbes LLC bought a new position in shares of Ralliant Corporation (NYSE:RAL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,535 shares of the company’s stock, valued at approximately $854,000.

Several other institutional investors and hedge funds have also made changes to their positions in RAL. GAMMA Investing LLC purchased a new stake in Ralliant during the 2nd quarter worth $56,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Ralliant during the second quarter worth about $1,799,000. Truist Financial Corp purchased a new stake in shares of Ralliant during the second quarter worth about $1,409,000. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Ralliant in the second quarter worth about $74,000. Finally, Robeco Institutional Asset Management B.V. purchased a new position in Ralliant in the second quarter valued at about $4,802,000.

Wall Street Analyst Weigh In

Several research firms have issued reports on RAL. Truist Financial initiated coverage on Ralliant in a report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective on the stock. Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $53.00 to $61.00 in a research note on Monday, December 8th. Oppenheimer raised their price objective on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Royal Bank Of Canada upped their target price on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Stock Performance

Ralliant stock opened at $52.86 on Friday. The company has a market cap of $5.96 billion and a PE ratio of 41.62. Ralliant Corporation has a 12 month low of $40.70 and a 12 month high of $55.25. The company has a fifty day moving average price of $51.52 and a two-hundred day moving average price of $46.68. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The business had revenue of $529.10 million during the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, March 9th. Ralliant’s payout ratio is presently 15.75%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.